Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.71% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Dec 31, 2024
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-047677General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-391.18% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
69.16% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-446.86% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
390.82% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
73.72% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- -0.03%
- Current
- 0.71%
- Delta
- 0.74%
- Previous
- -225.63%
- Current
- -391.18%
- Delta
- -165.55%
- Previous
- 58.86%
- Current
- 69.16%
- Delta
- 10.30%
- Previous
- -264.24%
- Current
- -446.86%
- Delta
- -182.62%
- Previous
- 281.20%
- Current
- 390.82%
- Delta
- 109.61%
- Previous
- 47.45%
- Current
- 73.72%
- Delta
- 26.26%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE CAPEX_INTENSITY_INCREASED →Transitioned To · CUE CASH_GENERATION_DECREASED →Transitioned To · CUE GROWTH_INCREASED →Transitioned To · CUE PROFITABILITY_DECREASED →Transitioned To · CUE R_AND_D_INTENSITY_INCREASED →Transitioned To · CUE SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.